Krystal Biotech, Inc. · NASDAQ:KRYS
Krystal Biotech — Q3 2024 Earnings Presentation
11 slides from Krystal Biotech's earnings presentation, Nov 4, 2024
Slide 1: Third Quarter 2024 Financial Results and Business Update
Third Quarter 2024 Financial Results and Business Update November 4, 2024 © Copyright 2024 Krystal Biotech, Inc. All rights reserved.
Slide 2: Forward Looking Statements and Disclosures
Forward Looking Statements and Disclosures This presentation, which includes the accompanying oral presentation, contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Krystal Biotec
Slide 3: 3Q 2024 Highlights
3Q 2024 Highlights ▪ VYJUVEK launch momentum continues in 3Q 2024 – CHMP opinion anticipated in 4Q 2024 and on track to launch in Europe in 1H 2025 – French authorities approved pre-marketing early reimbursed access for B-VEC in France – JNDA filed in Japan and on track to launch in Japan in 2H 2025
Slide 4: Over $250M in Net Revenue Since VYJUVEK Launch in August 2023
Over $250M in Net Revenue Since VYJUVEK Launch in August 2023 VYJUVEK Net Revenue ($M) $83.8 $70.3 $42.1 $45.3 $8.6 3Q 4Q 1Q 2Q 3Q 2023 2023 2024 2024 2024 ▪ Net revenue includes accrual for subset of U.S. patients on commercial insurance estimated to hit payment caps in 2024 ▪ Gross margin of 92% i
Slide 5: Over 460 Reimbursement Approvals as of October 2024
Over 460 Reimbursement Approvals as of October 2024 Reimbursement Approvals Breakdown Commercial Medicaid Other VYJUVEK Site of Care Payer 45% 40% 15% 3% Home Treatment In Office Treatment RDEB DDEB DEB Subtype 74% 26% 97% 6 months to 10 11 to 20 21 Years and Age Group Years Years Over 33% 25% 42% P
Slide 6: Tracking Towards Our Ambitious Two Year Penetration Target in US
Tracking Towards Our Ambitious Two Year Penetration Target in US Target: 720 Reimbursement Approvals Over 460 Reimbursement Approvals 3Q 2025 64% of Target October 2024 Launch 3Q 2023 Krystal | 6
Slide 7: Filing Submitted in Japan, On Track for Launches in Europe and Japan in 2025
Filing Submitted in Japan, On Track for Launches in Europe and Japan in 2025 Japan ✓ ODD received in December 2023 Europe ✓ JNDA submitted in October 2024 ✓ MAA validated by EMA in November 2023 ❑ Decision and launch expected 2H 2025 ✓ EU-GMP certification received May 2024 ✓ Pre-marketing early rei
Slide 8: Clinical Readouts This Year and Continuing into 2025
Clinical Readouts This Year and Continuing into 2025 Two more clinical readouts before end of year ❑ KB408 for alpha-1 antitrypsin deficiency lung disease ❑ KB707 for solid tumors 4Q 2024 3Q 2024 2025 ✓ Positive readout for KB301 in treatment of aesthetic indications ▪ Reported positive safety and e
Slide 9: Third Quarter 2024 Financial Highlights
Third Quarter 2024 Financial Highlights Cash and investments: $694.2 million as of September 30, 2024 Three Months Ended September 30 ($ in millions; except per share data) 2024 2023 Product revenue, net $83.8 $8.6 Cost of goods sold $6.7 $0.2 R&D expenses $13.5 $10.6 SG&A expenses $28.7 $23.7 Gain
Slide 10: Building Out a Portfolio of Redosable Genetic Medicines
Building Out a Portfolio of Redosable Genetic Medicines Indication Payload Preclinical Phase 1/2 Phase 3 Commercial Marketed in Dystrophic epidermolysis bullosa COL7A1 FDA Approved May 2023 the U.S. KB105 Lamellar ichthyosis TGM1 1H 2025 Ph 2 Start KB104 Netherton syndrome SPINK5 Dermatology Additio
Slide 11: Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs
Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs © Copyright 2024 Krystal Biotech, Inc. All rights reserved.